AMAG Pharmaceuticals said it hired Jefferies and Company as a financial adviser to explore strategic alternatives, including sale of the company.Earlier this month, the company said it would restructure its operations and explore strategic alternatives, after it called off its plan to purchase Allos Therapeutics.The search for a new chief executive is still on, AMAG said in a statement.Shares of the company, valued at about $339.2 million, closed at $16 on Wednesday on Nasdaq.
Allos Therapeutics, Inc. (Allos) is a biopharmaceutical company engaged in the development and commercialization of anti-cancer therapeutics. Shares of ALTH remained unchanged at $1.42. In the past year, the shares have traded as low as $1.39 and as high as $4.81. On average, 695198 shares of ALTH exchange hands on a given day and today's volume is recorded at 21682.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia (IDA). Shares of AMAG traded higher by 0.65% or $0.104/share to $16.10. In the past year, the shares have traded as low as $12.65 and as high as $21.22. On average, 273488 shares of AMAG exchange hands on a given day and today's volume is recorded at 46131.
Source
